Press Releases

Latest News & Archive

 
 
     
 
 
  2018
 
     
 
October 8, 2018
 
Affimed Places AFM11 (CD19/CD3-Targeting T cell Engager) Phase 1 Program on Clinical Hold
 
 
August 30, 2018
 
Affimed to Present at the 2018 Wells Fargo Securities Healthcare Conference
 
 
August 27, 2018
 
Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics
for Multiple Cancer Targets
 
 
August 8, 2018
 
Affimed Reports Financial Results for Second Quarter 2018 and Operational Progress
 
 
August 3, 2018
 
Affimed Announces Second Quarter 2018 Financial Results and Corporate Update Conference Call
 
 
June 15, 2018
 
Affimed Announces Updated Data of AFM13 in Combination with Keytruda® (Pembrolizumab) in Patients with Relapsed/Refractory Hodgkin Lymphoma Presented at the European Hematology Association 23rd Congress
 
 
May 30, 2018
 
Affimed to Present at the Jefferies Global Healthcare Conference
 
 
May 18, 2018
 
Affimed Announces Annual General Meeting of Shareholders
 
 
May 15, 2018
 
Affimed Reports Financial Results for First Quarter 2018
 
 
May 8, 2018
 
Affimed Announces First Quarter 2018 Financial Results and Corporate Update Conference Call
 
 
May 3, 2018
 
Affimed Introduces ROCK(TM) Platform for Tailored Immune Cell Engagers
 
 
May 3, 2018
 
Affimed to Present at Deutsche Bank's 43rd Annual Health Care Conference
 
 
April 16, 2018
 
Affimed Presents Poster at AACR Highlighting Progress Toward Novel EGFR-targeting Therapy
 
 
March 20, 2018
 
Affimed Reports Financial Results for Fourth Quarter and Year End 2017
 
 
March 19, 2018
 
Affimed Appoints Dr. Leila Alland as Chief Medical Officer
 
 
March 15, 2018
 
Affimed to Present Data on AFM24 at AACR Annual Meeting 2018
 
 
March 13, 2018
 
Affimed Announces Fourth Quarter and Year End 2017 Financial Results and Corporate Update Conference Call
 
 
March 8, 2018
 
Affimed to Present at the Cowen and Company 38th Annual Health Care Conference
 
 
February 15, 2018
 
Affimed Announces Closing of Public Offering of Common Stock and Exercise of Underwriters’ Option to Purchase Additional Shares
 
 
February 13, 2018
 
Affimed Announces Pricing of Public Offering of Common Stock
 
 
February 12, 2018
 
Affimed Announces Proposed Public Offering of Common Stock
 
 
February 1, 2018
 
Affimed Reports New Data for AFM13 from Two Separate Clinical Trials in Hodgkin and CD30-Positive Lymphomas
 
     
     
 
  Past Press Releases
2017 - 2010
         
 
  For more information contact:  
   
 

Head of Investor Relations

Greg Gin


ir@affimed.com

 

Head of Communications

Dr. Anca Alexandru


media@affimed.com

 
To be added to our press
release distribution system:
please click here  
 
 
 
 



 
  Impressum Disclaimer Data Privacy